Business Context and Reporting Period
Cytosorbents Corp (CTS) filed a Form 8-K on October 1, 2024, reporting an "Other Event" under Item 8.01. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital raising authorization.
Material Changes
The material change reported is the authorization of an "at the market" equity offering program. Key details include:
- Program Type: At-the-market (ATM) offering under a Registration Statement on Form S-3 (No. 333-281062).
- Agreement Date: Open Market Sale Agreement dated December 30, 2021, with Jefferies LLC.
- Maximum Offering Amount: Up to $20,000,000 of Common Stock.
- Regulatory Status: The registration statement was amended on September 26, 2024, and declared effective by the SEC on September 30, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or specific risk factors beyond the standard legal opinion regarding the issuance of shares. Morgan, Lewis & Bockius LLP issued a legal opinion confirming the legality of the issuance and sale of the offered shares.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to $20 million in shares.
- Review the full Open Market Sale Agreement with Jefferies LLC for specific terms and termination rights.
- Monitor subsequent filings to track the actual volume of shares sold under this program.
- Confirm the company's current cash position to understand the urgency or strategic intent of this capital raise.